Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Kubicka

Showing results (11-20 of 67) with videos related to

Pageof 7
Sort By:
Der Internist|December 21, 2006
[Systemic treatment of liver and biliary tumors]N P Malek, T Greten, S Kubicka
Der Internist|February 12, 1998
[Hepatocellular carcinoma: diagnosis and multi-modality therapy]S Kubicka, L Rudolph, M P Manns
Hepatology (Baltimore, Md.)|April 1, 1997
Target gene modulation in hepatocellular carcinomas by decreased DNA-binding of p53 mutationsS Kubicka, C Trautwein, M Niehof, et al.
Digestive Diseases (Basel, Switzerland)|April 6, 2002
Prevention of hepatocellular carcinoma in chronic liver disease: molecular markers and clinical implicationsF N Plesch, S Kubicka, M P Manns
Der Internist|November 2, 2001
[Gene and immunotherapy of liver diseases]T Cantz, M Ott, S Kubicka, et al.
Cancer Treatment Reviews|July 25, 2017
Treatment decisions in metastatic colorectal cancer - Beyond first and second line combination therapiesA Vogel, R D Hofheinz, S Kubicka, et al.
Journal of Hepatology|October 1, 1995
Low incidence of p53 mutations in European hepatocellular carcinomas with heterogeneous mutation as a rare eventS Kubicka, C Trautwein, H Schrem, et al.
Hepatology (Baltimore, Md.)|March 30, 1999
Two control elements in the hepatitis B virus S-promoter are important for full promoter activity mediated by CCAAT-binding factorC T Bock, S Kubicka, M P Manns, et al.
Metabolic Brain Disease|September 1, 1995
Pallidal lesions in patients with liver cirrhosis: clinical and MRI evaluationK Weissenborn, C Ehrenheim, A Hori, et al.
Hepatology (Baltimore, Md.)|August 29, 2000
Hyperstimulation with interleukin 6 inhibits cell cycle progression after hepatectomy in miceT Wüstefeld, T Rakemann, S Kubicka, et al.
Pageof 7

Showing results (11-20 of 67) with videos related to

Sort By:
Pageof 7
Der Internist|December 21, 2006
[Systemic treatment of liver and biliary tumors]N P Malek, T Greten, S Kubicka
Der Internist|February 12, 1998
[Hepatocellular carcinoma: diagnosis and multi-modality therapy]S Kubicka, L Rudolph, M P Manns
Hepatology (Baltimore, Md.)|April 1, 1997
Target gene modulation in hepatocellular carcinomas by decreased DNA-binding of p53 mutationsS Kubicka, C Trautwein, M Niehof, et al.
Digestive Diseases (Basel, Switzerland)|April 6, 2002
Prevention of hepatocellular carcinoma in chronic liver disease: molecular markers and clinical implicationsF N Plesch, S Kubicka, M P Manns
Der Internist|November 2, 2001
[Gene and immunotherapy of liver diseases]T Cantz, M Ott, S Kubicka, et al.
Cancer Treatment Reviews|July 25, 2017
Treatment decisions in metastatic colorectal cancer - Beyond first and second line combination therapiesA Vogel, R D Hofheinz, S Kubicka, et al.
Journal of Hepatology|October 1, 1995
Low incidence of p53 mutations in European hepatocellular carcinomas with heterogeneous mutation as a rare eventS Kubicka, C Trautwein, H Schrem, et al.
Hepatology (Baltimore, Md.)|March 30, 1999
Two control elements in the hepatitis B virus S-promoter are important for full promoter activity mediated by CCAAT-binding factorC T Bock, S Kubicka, M P Manns, et al.
Metabolic Brain Disease|September 1, 1995
Pallidal lesions in patients with liver cirrhosis: clinical and MRI evaluationK Weissenborn, C Ehrenheim, A Hori, et al.
Hepatology (Baltimore, Md.)|August 29, 2000
Hyperstimulation with interleukin 6 inhibits cell cycle progression after hepatectomy in miceT Wüstefeld, T Rakemann, S Kubicka, et al.
Pageof 7